Finding the onset of COVID-19 - a correlation analysis with influenza epidemic around the world

Yixue Yang  
Jilin University

Bo Li  
Jilin University

Nan Yao  
Jilin University

Yingpei Guo  
Jilin University

Han Wang  
Jilin University

Junwei Tian  
Jilin University

Ruirui Guo  
Jilin University

Xuhan Wang  
Jilin University

Jiwei Jia (jiajiwei@jlu.edu.cn)  
Jilin University

Siyu Liu (liusiyu@jlu.edu.cn)  
Jilin University

Research Article

Keywords: COVID-19, influenza, time-series, ARIMA, onset

Posted Date: November 5th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1052161/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Finding the onset of COVID-19 - a correlation analysis with influenza epidemic around the world

Yixue Yang\textsuperscript{1}, Bo Li\textsuperscript{1}, Nan Yao\textsuperscript{1}, Yinpei Guo\textsuperscript{1}, Han Wang\textsuperscript{1}, Junwei Tian\textsuperscript{2}, Ruirui Guo\textsuperscript{1}, Xuhan Wang\textsuperscript{1}, Jiwei Jia\textsuperscript{2,3,*}, Siyu Liu\textsuperscript{1,4,*}

\textsuperscript{1}Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, P. R. China.
\textsuperscript{2}Department of Computational Mathematics, School of Mathematics, Jilin University, Qianjin Street No. 2699, Changchun, 130021, P. R. China
\textsuperscript{3}Jilin National Applied Mathematical Center, Jilin University, Qianjin Street No.2699, Changchun, 130012, P. R. China
\textsuperscript{4}Key Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, Jilin University, Changchun, 130012, P.R. China

*Corresponding authors

Name: Jiwei Jia & Siyu Liu;
E-mail: jiajiwei@jlu.edu.cn; liusiyu@jlu.edu.cn.

Abbreviations

COVID-19: Coronavirus Disease 2019;
CI: Confidence Interval;
ARIMA: Autoregressive Integrated Moving Average Model;
ILI: Influenza Like Illness;
NPIs: Non-pharmaceutical Interventions;
SARS-CoV: Severe Acute Respiratory Syndrome Coronavirus;
WMI: Weekly Morbidities of Influenza;
WMC: Weekly Morbidities of Coronavirus Disease 2019;
EVALI: electronic cigarette or vaping product use associated lung injury;
K-S: Kolmogorov-Smirnov.
Abstract

Background. COVID-19 showed similar and overlapping symptoms compared with seasonal influenza. It is difficult to distinguish them, especially in the early stage of the outbreak. The confluence of the two diseases might result in considerable morbidity, it is doubtful that whether COVID-19 had already affected the morbidity of influenza earlier than the first report.

Methods. We conducted Kolmogorov-Smirnov Test and Kruskal Wallis Test to discover seasonal and regional distributions of influenza and COVID-19. Cluster analysis was utilized to explore possible influence factors. Spearman Test was carried out for analyzing correlations between the two diseases. We employed Arima Model to predict time series of WMI. We proved differences between the forecasted and the original time series of influenza from 2019 to 2021 by Mann-Whitney U Test. Then we observed first abnormal peaks on the time series, tracing back to the onset of COVID-19 affecting influenza compared with the first-report time.

Results. WMI and WMC varied significantly in four seasons, five continents and the ten selected countries. Cluster analysis divided the data into two groups according to country, continent, population and morbidity. WMI of China, Israel, Honduras, Morocco and Nigeria were correlated with WMC. The forecasted and the original time series of influenza from 2019 to 2021 were significantly different. Compared with the forecasted one, some abnormal peaks firstly appeared on the original time series of influenza around Dec.31st, 2018 on Austria, Norway, Morocco and Nigeria, Jan.28th, 2019 on South Africa, Apr.8th, 2019 on Marshall Islands, Jul.7th, 2019 on America, Sep.30th, 2019 on China and Israel, Mar.11th, 2020 on Honduras.

Conclusions. Winter and autumn were the high incidence season for influenza and COVID-19, respectively. Oceania and Americas owned the highest incidence rate for these two diseases. Human immunity, continents, countries’ policies and population were possible influence factors. Only in Honduras, the first reported COVID-19 case happened concurrently with the abnormal value of the ILI. And in the rest of the included countries, COVID-19 might happen earlier than its first reports. Among these regions, COVID-19 might firstly affect Africa in the first week of 2019.
**Keywords:** COVID-19; influenza; time-series; ARIMA; onset
1. Introduction

COVID-19 was firstly reported in the winter of 2019 accompanied with several symptoms including coughing, fever and so on\[1\]. It has been being emergent to control this disease effectively for its readily communicable feature (higher transmissibility than seasonal influenza and SARS-CoV) as well as pandemic situation\[2-5\].

Many countries have recommended or imposed various policies, and the effectiveness of implementation relied on people’s awareness, knowledge and attitude towards COVID-19\[6-8\]. This was one of the reasons that made the status of the epidemic control varied greatly in different countries around the world. Most respiratory infectious diseases were usually self-limiting\[9\] except for a few serious consequences in specific populations\[10-16\], making it difficult to detect and diagnose them in the early stage. At the same time, their symptoms were often partially similar and overlapping, for example, seasonal influenza and COVID-19 share the fever and respiratory symptoms\[17-19\], making it difficult to distinguish them. What’s more, COVID-19, as a new disease, lacked prior diagnostic experience and prompt awareness. These facts led us to explore whether COVID-19 has been misdiagnosed as seasonal influenza earlier than its first report around the world.

Recently, the traceability of COVID-19 attracts much of attention. It have been reported that COVID-19 cases might appear earlier than its first reports in some countries\[20-22\]. A study confirmed that the confluence of COVID-19 and influenza might result in considerable morbidity\[23\]. For tracing back to the earliest misdiagnosis and confluence, we conducted statistical analysis and time-series analysis. We explored the distribution characteristics of COVID-19 and influenza, the correlation between the two diseases, the possible influencing factors, and abnormal time series of seasonal influenza recent years. During these processes, we solved difficulties like stability transformation of time series and unification of data scale. To our best knowledge, the earliest incidence time of COVID-19 is still an open problem. We hope our results will provide guidance to find the possible sources of COVID-19 and to carry out the prevention and control measures well.
2. Materials and Methods

2.1. Collection of Data

To reflect the situation of all continents in the world, the number of countries and the total population in each continent were used as the references for sampling in this study. On the one hand, the number of countries included in each continent should be consistent with the proportion of countries among the five continents (Asia: Europe: Americas: Oceania: Africa = 48:48:51:21:58 \(\approx\) 2:2:2:1:3). On the other hand, the relative size of the population included in each continent should be consistent with the relative size of the population among the five continents (Asia > Africa \(\approx\) Americas > Europe > Oceania).

Besides, countries included should provide both the data of COVID-19 cases in 2020 and the data of influenza-like illness from 2011 to 2020. Countries missing too much of data were excluded.

According to the above criteria, China, Israel, Austria, Norway, America, Honduras, Marshall Islands, Morocco, Nigeria and South Africa were included in this study. Data of these ten countries was obtained from WHO\(^{[24,25]}\), Chines National Influenza Center\(^{[26]}\) and Country meters\(^{[27]}\) websites.

2.2. Data Processing

To address the missing ILI data according to the periodic features, if whole-year new cases data was missing, the data of the nearest year would be used to replace the missing one; if non-whole-year new cases data was missing, 0 would be used to replace the missing data. We used formulas listed below to calculate WMI and WMC.

\[
WMI = \frac{a}{c}; \quad WMC = \frac{b}{c}
\]

(a: number of new influenza like illness per week; b: number of new COVID-19 cases per week; c: annual population)

2.3. Statistical Analysis

We conducted Kolmogorov-Smirnov Test and Kruskal Wallis Test to search for
season and area distribution characteristics of influenza and COVID-19. To find the high incidence seasons, we stipulated four seasons as Table 1. To find the high incidence region, we stipulated that different regions included Asia, Europe, Americas, Oceania and Africa. Kolmogorov-Smirnov Test was used to test normality. Then Kruskal Wallis Test was used to verify the significant differences amid four seasons as well as amid five regions.

We used cluster analysis to explore possible influence factors of the distribution differences of the two diseases. After operating Kolmogorov-Smirnov Test and Kruskal Wallis Test for verifying the differences amid ten countries included, we conducted K-means cluster analysis to look for the features of different clusters during the epidemics.

Spearman Test was carried out for correlations between WMI and WMC in the same country. As the correlations were confirmed, we continued to do time-series analysis for exploring the possible appearance of COVID-19.

IBM SPSS Statistics 24 was used to conduct statistical analysis. P<0.05 was considered to be significant.

2.4. Time-series Analysis

In this study, Python 3 was used to conduct time-series Analysis. We used Dickey-Fuller Test to examine the stationarity of time series. Then we transformed non-stationary time series into stationary time series. Arima Model was used to build time series.

We used original WMI data to build ARMA Models of influenza from 2011 to 2018. Then we used the ARMA Models to forecast time series of influenza from 2019 to 2021 (named as the forecasted time series). At the same time, we used original WMI data (named as the original time series) to build ARMA Models of influenza from 2019 to 2021 and compared with the forecasted time series. Then we proved differences between the forecasted and the original time series of influenza from 2019 to 2021 by Mann-Whitney U Test. Finally, we observed abnormal peaks on the forecasted time series compared with the original one from 2019 to 2021. According
to the earliest abnormal peak, we judged the probably earliest time when COVID-19 affected influenza time series.

2.5. Quality Control

In this study, countries were randomly stratified sampling according to the inclusion and exclusion criteria. All the results were verified repeatedly by two investigators.

3. Results

3.1. Data and Study Population

The ratio of country numbers of Asia, Europe, Americas, Oceania and Africa was 48:48:51:21:58 (2:2:2:1:3). In addition, on Jan.1st, 2021, the population of Asia was about 4670867280, that of Europe was about 749874114, that of Americas was about 1028933407, that of Oceania was about 43061875, that of Africa was about 1358427180[27], therefore the relationship of population was Asia > Africa ≈ Americas > Europe > Oceania in general.

Finally, we achieved new ILI cases per week in 2011-2021 (started from Jan.3rd; ended on Jan.17th, 2021) and daily COVID-19 new cases in 2020-2021 (started from Dec.30th, 2019; ended on Jan.17th, 2021) from 10 countries (Table 2), which we used to calculate weekly morbidity.

3.2. Distribution Features of Influenza and COVID-19

WMI of eight countries in northern hemisphere and of two countries in southern hemisphere looked different in four seasons in Figure 1. Then the K-S Test’s result showed nonnormal distribution (P<0.001, Figure 2, Table 3), thus we conducted Kruskal Wallis Test, proving that mean WMI of four seasons were significantly different (P<0.001, Figure 2, Table 3) with the highest grade of season 4 (winter, grade=3211.77, Figure 2, Table 3).

In Figure 3, curves about WMC of eight countries in northern hemisphere and of two countries in southern hemisphere behaved different appearances in four seasons.
Then the K-S Test’s result showed nonnormal distribution (P<0.001, Figure 4, Table 3), thus we operated Kruskal Wallis Test, confirming that the mean of WMC for four seasons were significantly different (P<0.001, Figure 4, Table 3) with the highest grade of season 3 (autumn, grade=334.91, Figure 4, Table 3).

Curves about WMI of ten countries trended differently in five continents in Figure 5. Then the K-S Test’s result showed nonnormal distribution (P<0.001, Figure 5, Table 3), thus we conducted Kruskal Wallis Test, gaining significant difference of mean WMI between five continents (P<0.001, Figure 5, Table 3). Continent 4 had the highest grade (Oceania, grade= 4003.91, Figure 5, Table 3).

Figure 6 depicted different curves about WMC of ten countries in five continents. Then the K-S Test’s result showed nonnormal distribution (P<0.001, Figure 6, Table 3), thus we conducted Kruskal Wallis Test, testify that the mean of WMC for five continents were significantly different (P<0.001, Figure 6, Table 3). Continent 3 (Americas) had the highest grade (grade= 356.23, Figure 6, Table 3).

3.3. Possible Influence Factors of Influenza and COVID-19

Kolmogorov-Smirnov Tests showed that WMI and WMC of the ten countries were all nonnormal (P<0.001, Table 4), hence Kruskal Wallis Tests were choseed which proved significantly differences of the mean WMI (P<0.001, Table 5) and the mean WMC (P<0.001, Table 5) between ten countries. The highest grade of the two Kruskal Wallis Tests were country 7 (Marshall Islands, grade=4003.91, Table 5) and country 5 (America, grade=405.85, Table 5).

Cluster analysis for possible influencing factors of influenza divided the data into two clusters according to different cluster centers of country, continent, population and morbidity (cluster centers of cluster 1 including country 1, continent 1, population of 1406170204 and morbidity of 0.0000420151; cluster centers of cluster 2 including country 6, continent 3, population of 69267633 and morbidity of 0.0101980371; Table 5). And the same analysis for COVID-19 divided the data into two clusters according to different cluster centers of country, continent, population and morbidity (cluster centers of cluster 1 including country 6, continent 3, population of 73603300 and
morbidity of 0.0477510497; cluster centers of cluster 2 including country 1, continent 1, population of 1436838423 and morbidity of 0.0001248127; Table 6). As we could see, China was divided into different cluster from other countries.

3.4. Correlation between Influenza and COVID-19

WMI of China ($\rho =0.412$, $P=0.002$) and Honduras ($\rho =0.527$, $P<0.001$) were positive correlated with WMC in 2020-2021 (Table 7); WMI of Israel ($\rho =-0.402$, $P=0.002$), Morocco ($\rho =-0.639$, $P<0.001$) and Nigeria ($\rho =-0.449$, $P=0.001$; Table 7) were negative correlated with WMC in 2020-2021 (Table 7); WMI of Austria ($\rho =-0.159$, $P=0.245$), Norway ($\rho =-0.057$, $P=0.678$), America($\rho =-0.227$, $P=0.095$), Marshall Islands ($\rho =0.092$, $P=0.503$) and South Africa ($\rho =-0.238$, $P=0.080$) were uncorrelated with WMC in 2020-2021 (Table 7).

3.5. Time-series Analysis

We succeeded in building and plotting the original WMI series and the ARMA Models of influenza of ten countries from 2011 to 2018 (Figure 7), the original WMI series (the original time series) and the ARMA Models of influenza of ten countries from 2019 to 2021 (Figure 8), and the original time series and the forecasted time series of influenza from 2019 to 2021 (Figure 9). The AR(p), MA(q), d and RMSE value of each ARMA Model were listed in Table 8.

K-S Tests showed nonnormal distribution of the original time series and the forecasted time series of influenza from 2019 to 2021 ($P<0.001$, Table 9) apart from the forecasted time series of Nigeria ($P=0.2000$, Table 9), then we proved that the two time series of America ($P=0.012$) and other nine countries ($P<0.001$) were significantly different by Mann-Whitney U Test (Table 9). So far, the forecasted time series were proved to be significantly different from the original time series of influenza from 2019 to 2021.

Finally, because the ARMA Models from 2019 to 2021 didn’t completely fitted the original time series, we still observed the original time series and the forecasted time series of influenza from 2019 to 2021 in a same picture (Figure 9), finding some
abnormal peaks and estimating the possible start time of COVID-19. In China, the first abnormal peak started from Sep.30th, 2019; In Israel, the first abnormal peak started from Sep.30th, 2019; In Austria, the first abnormal peak started from Dec.31st, 2018; In Norway, the first abnormal peak started from Dec.31st, 2018; In America, the first abnormal peak started from Jul.22nd, 2019; In Honduras, the first abnormal peak started from Mar.11th, 2020; In Marshall Islands, the first abnormal peak started from Apr.8th, 2019; In Morocco, the first abnormal peak started from Dec.31st, 2018; In Nigeria, the first abnormal peak started from Dec.31st, 2018; In South Africa, the first abnormal peak started from Jan.28th, 2019 (Table 10).

4. Discussion

WMI and WMC of the ten countries were significantly different in the four seasons. Since season 4 of WMI performed the highest grade, influenza would be more prevalent in winter. And season 3 of WMC performed the highest grade, COVID-19 would be more prevalent in autumn. A previous study had shown that high incidence of influenza appeared majorly in autumn and winter in temperate zone, and could occurred throughout the year in tropical zone[28]. Among the countries involved in our study, most of China, Israel, Austria, Norway, America, Morocco and South Africa located in temperate zone, while the other three countries were tropical countries. This confirmed that our conclusions of high incidence season of influenza and COVID-19 were scientific to a certain extent. Besides, a study summarized that all over world respiratory virus would be more easier to spread in winter including influenza virus and human coronavirus[29], which was consistent with our results. Nevertheless, we found that COVID-19 would be more prevalent in autumn than winter worldwide, which uncovered from the side that it might happen earlier in autumn than its first observation in winter.

In this study, WMI of ten countries were also proved to be significantly different in five continents as continent 4 performed the highest grade, presenting that influenza would be more prevalent in Oceania. A research speculated that new seasonal influenza A viruses might appear in Asia, then firstly spread to Oceania with
quick variation and reproduction\textsuperscript{30}. However, our study showed that COVID-19 would be more prevalent in Americas so far as continent 3 performed the highest grade in variance analysis of WMC of ten countries in five continents. The fact from WHO that as of Apr. 2021 the number of COVID-19 diagnoses in the Americas was the largest among the five continents seemed to confirm this as well\textsuperscript{25}.

Then we explored influence factors of the two epidemics to try to explain all the differences to some extent. Firstly, the seasonal variations of the two epidemics might be attributed to seasonal human immunity. For example, it has been confirmed that seasonal solar radiation\textsuperscript{31} and vitamin D level\textsuperscript{32,33} could influence human immunity. As solar radiation was the lowest in winter in temperate zone, vitamin D would be deficient during this time\textsuperscript{34-37}. Secondly, we have found that the mean WMI of the ten countries were significantly different in the highest grade of country 7 (Marshall Islands), and the mean WMC of the ten countries were significantly different in the highest grade of country 5 (America), reminding us that different countries behaved divergent morbidity of the two diseases. Combined with the cluster analysis results which divided the data into two clusters according to different cluster centers of country and the country conditions including continent and population, different countries with different conditions might be one of the important influence factors of influenza and COVID-19. Besides, we noticed that China was divided into different cluster from other countries in both of the epidemics. Since China posseses the largest population\textsuperscript{27}, the first reported COVID-19 case as well as rapid government actions, we also considered influence factors from aspect of country’s policies and population. Several studies have shown that morbidity of influenza could be decreased after conduction of NPIs\textsuperscript{38,39}. And a study analyzed whether various governmental policies for addressing the COVID-19 pandemic in 177 countries were appropriate, finding different reaction degrees of these countries and suggesting that governments should promote their response facing COVID-19\textsuperscript{40}. Therefore, we speculated that country’s policy was one of the influence factors. What’s more, we noticed that WHO had informed influenza spreading easily in crowded places\textsuperscript{41}. And a paper reported that American population-level interest in telehealth was positively
correlated with increased COVID-19 cases, however, the present telehealth level might not satisfied their population demand[42]. These studies supported our hypothesis about the impact of population on influenza and COVID-19. Therefore, we believed that different countries with different human immunity, continents, policies and population were possible influence factors of influenza and COVID-19.

Back to the doubt about whether COVID-19 happened earlier than its first observation, we conducted correlation analysis and time-series analysis. Figure 9 and Table 10 depicted that compared to the forecasted time series, the original time series of all the included countries from 2019 to 2021 behaved abnormal. There was a significant difference between the original and the forecasted time series of influenza from 2019 to 2021. We found reports about their first cases and compared the first reported time with the date of first abnormal peaks (Table 10). Shown that the most severe public affairs since 2019 was COVID-19, we had reasonable doubts about COVID-19 might impacting influenza epidemics early when the first abnormal peaks appeared in these ten countries. In a word, In Morocco, the COVID-19 might start from Dec.31th, 2018 though the first case was reported on Mar.2nd, 2020; the COVID-19 might make effects from Dec.31th, 2018 although the first case was reported on Feb.27th, 2020 in Nigeria; the COVID-19 might have an impact on influenza from Sep. 30th, 2019 while the first case was reported on Dec.31st, 2019 in China; and from Sep.30th, 2019 though the first case was reported on Feb.20th, 2020 in Israel. Please notice that Honduras is a mountainous country with excellent ecological environment, the trade and exchange with outsiders are relative limited, so the impact from outside is weak there. The abnormal value indicated that the COVID-19 might appear from Mar.11th, 2020 which was concurrent with the first reported case in Honduras, which illustrated that the number of ILI confirmed cases was effected by the COVID-19 to some extent. This result verifies the effectiveness of our method.

Considered that only the WMI of China, Israel, Honduras, Morocco and Nigeria were correlated with WMC in 2020-2021, we speculated that in these five countries, influenza might also impact COVID-19 itself except for the misdiagnosis led by
similar and overlapping symptoms between the two diseases\cite{17-19,43}, thus the abnormal peaks of these five countries might come from the correlation between the two diseases as well as misdiagnosis. And the impact from COVID-19 on influenza in the other five countries Austria, Norway, America, Marshall Islands and South African were not that strong especially, but the misdiagnosis still exist according to the abnormal peak value. Among the five countries, abnormal peaks started earliest in Morocco and Nigeria from Dec.31st, 2018. These two countries were African countries, reminding us that perhaps Africa was affected earlier than other continents. We need more data from other continents and countries to verify.

There were still some deficiencies in our study. The original data of influenza on WHO website missed partly, and it didn’t contain the data of different type of influenza. Nevertheless, given that we have handled the missing values, and we have included the data of ten years which was long enough, even if there is no typing in the original data, the overall trend of influenza would still show its seasonality, thus we believed that these data would be meaningful and significant.

5. Conclusion

High incidence season of influenza was winter, and Oceania owned the highest incidence rate. High incidence season of COVID-19 was autumn, and Americas owned the highest incidence rate. Human immunity in different countries, continents, countries’ policies and population possibly influenced the distribution differences. Besides, COVID-19 might happen earlier than its first reports in China, Israel, Austria, Norway, America, Marshall Islands, Morocco, Nigeria and South Africa and affected ILI cases, while it happened concurrently when it was first reported in Honduras. In these regions, COVID-19 might made effects earliest in Africa in the first week in 2019.

Declarations

Funding: Our research is supported by National Natural Science Foundation of China (Grant No.11901234), Scientific Research Project of Education Department of Jilin
Province (Grant No.JJKH20200933KJ) and the Fundamental Research Funds for the Central Universities, JLU (Grant No. 93K172020K27).

Conflicts of interest: All the authors have no conflicts of interest.

Authors' contributions
Siyu Liu and Jiwei Jia designed the study and settled the method; Yixue Yang, Nan Yao, Yinpei Guo, Han Wang and Junwei Tian collected the data; Yixue Yang and Nan Yao analyzed the data; Yixue Yang drafted the first manuscript; Yixue Yang, Nan Yao, Yinpei Guo and Han Wang conducted the visualization; Yixue Yang, Ruirui Guo and Xuhan Wang validated the results; Bo Li, Siyu Liu and Jiwei Jia participated in amending the manuscript.

References
[1] Adhikari SP, Meng S, Wu Y-J, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review[J]. Infect Dis Poverty. 2020, 9(1):1-12.
[2] Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses[J]. J Adv Res. 2020, 24: 91-98.
[3] Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus[J]. J Travel Med. 2020.
[4] World Health Organization (WHO). Pandemic Influenza Severity Assessment (PISA): A WHO guide to assess the severity of influenza epidemics and pandemics[J]. Geneva: WHO. 2017.
[5] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic[J]. Acta Biomed. 2020, 91(1):157-160.
[6] Azlan AA, Hamzah MR, Sern TJ. Public knowledge, attitudes and practices towards COVID-19: A cross-sectional study in Malaysia[J]. PLoS One. 2020, 15(5):e0233668.
[7] Geana MV. Kansans in the middle of the pandemic: risk perception, knowledge, compliance with preventive measures, and primary sources of information about COVID-19[J]. Kans J Med. 2020, 13:160-164.
[8] Graffigna G, Barello S. Measuring Italian citizens’ engagement in the first wave of the COVID-19 pandemic containment measures: A cross-sectional study[J]. medRxiv. 2020, 15(9):e0238613.
[9] Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza[J]. Clin Infect Dis. 2019, 6: 895-902.

[10] Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. Lancet. 2018.

[11] Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children[J]. N Engl J Med. 2006, 1: 31-40.

[12] Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States[J]. JAMA. 2010, 15: 1517-1525.

[13] Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008[J]. Clin Infect Dis. 2012, 10: 1427-1436.

[14] Centers for Disease Control and Prevention. Disease Burden of Influenza [DB/OL]. https://www.cdc.gov/flu/about/burden/index.html, 2018-11-08.

[15] Thompson WW, Moore MR, Weintraub E, Cheng PY, Jin X, Bridges CB, et al. Estimating influenza-associated deaths in the United States[J]. Am J Public Health. 2009, 99(2): S225-30.

[16] Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States[J]. JAMA. 2004, 11: 1333-1340.

[17] Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. N Engl J Med. 2020, 382(8): 727-733.

[18] Solomon, D. A., Sherman, A. C. & Kanjilal, S. Influenza in the COVID-19 Era[J]. JAMA. 2020, 324(13): 1342-1343.

[19] Zayet, S. et al. Clinical features of COVID-19 and influenza: a comparative study on Nord 519 Franche-Comte cluster[J]. Microbes Infect. 2020, 22(9): 481-488.

[20] Lu Chengkuan. The United States should announce the truth of EVALI in 2019 (in Chinese)[N]. Science and Technology Daily, 2021-08-02 (001).

[21] Yu Yuan Tan Tian. [Tracing back to the United States] We contacted these Americans. They said that they had COVID-19 very early...... (in Chinese)[ER/OL]. https://mp.weixin.qq.com/s/uk2dI6pSM6zQDDIATEh-7w, 2021-08-13.

[22] Wang Hui. The Italian media traced back to Fort Detrick Biological Laboratory. CNN felt anxious: unfamous tabloid (in Chinese)[N]. Guancha Syndicate, 2021-08-12.

[23] Gostin, L. O. & Salmon, D. A. The Dual Epidemics of COVID-19 and Influenza: Vaccine 514 Acceptance, Coverage, and Mandates[J]. JAMA. 2020, 324(4): 335-336.

[24] World Health Organization. WHO FLUMART OUTPUTS [DB/OL].
https://apps.who.int/flumart/Default?ReportNo=16, 2021-01-30.
[25] World Health Organization. WHO Coronavirus (COVID-19) Dashboard [DB/OL]. https://covid19.who.int, 2021-01-23.
[26] Chinese National Influenza Center. Influenza Weekly Report [DB/OL]. http://www.chinaivdc.cn/cnic/zyzx/lgzb/index_1.htm, 2021-02-04.
[27] Countries. World population[DB/OL]. https://countrymeters.info/cn/World, 2021-02-06.
[28] TAMERIUS J, NELSON M I, ZHOU S Z, et al. Global influenza seasonality: reconciling patterns across temperate and tropical regions[J]. Environ Health Perspect. 2011, 119(4): 439-445.
[29] Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections[J]. Annu Rev Virol. 2020, 7(1):83-101.
[30] Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, Hampson AW, Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, Kageyama T, Komadina N, Lapedes AS, Lin YP, Mosterin A, Obuchi M, Odagiri T, Osterhaus AD, Rimmelzwaan GF, Shaw MW, Skepner E, Stohr K, Tashiro M, Fouchier RA, Smith DJ. The global circulation of seasonal influenza A (H3N2) viruses. Science[J]. 2008, 320(5874): 340-346.
[31] Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D[J]. Epidemiol Infect. 2006, 134(6): 1129-1140.
[32] Ioia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect. 2007, 135: 1095-1096.
[33] Ginde AA, Mansbach JM, Camargo CA.. Jr Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey[J]. Arch Intern Med. 2009, 169: 384-390.
[34] Brustad M, Edvardsen K, Wilsgaard T, Engelsen O, Aksnes L, Lund E. Seasonality of UV-radiation and vitamin D status at 69 degrees north[J]. PhotochemPhotobiol Sci. 2007, 6(8): 903-908.
[35] Holick MF. High prevalence of vitamin D inadequacy and implications for health[J]. Mayo Clin Proc. 2006, 81(3):353-373.
[36] Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story[J]. J Bone Miner Res. 2007, 22(2):V28-33.
[37] Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin[J]. J Clin Endocrinol Metab. 1988, 67(2):373-378.
[38] COWLING B J, ALI S T, NG T W Y, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study[J]. Lancet Public Health. 2020,5(5):e279-e88.
[39] SAKAMOTO H, ISHIKANE M, UEDA P. Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in Japan [J]. Jama. 2020, 323(19): 1969-1971.
[40] Dewi A, Nurmandi A, Rochmawati E, et al. Global policy responses to the COVID-19 pandemic: proportionate adaptation and policy experimentation: a study of country policy response variation to the COVID-19 pandemic[J]. Health Promot Perspect. 2020, 10(4):359-365.

[41] World Health Organization. Influenza (Seasonal)[DB/OL]. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

[42] Hong YR, Lawrence J, Williams D Jr, Mainous III A. Population-Level Interest and Telehealth Capacity of US Hospitals in Response to COVID-19: Cross-Sectional Analysis of Google Search and National Hospital Survey Data[J]. JMIR Public Health Surveill. 2020, 6(2):e18961.
|                  | Spring/Season 1 | Summer/Season 2 | Autumn/Season 3 | Winter/Season 4 |
|------------------|-----------------|-----------------|-----------------|-----------------|
| Northern hemisphere | March       | September       | June            | December       |
| Southern hemisphere | September | June            | December       | June            |
| Northern hemisphere | June       | December        | September       | March           |
| Southern hemisphere | December | March           | September       | June            |
| Northern hemisphere | September | March           | April           | January         |
| Southern hemisphere | March     | April           | January         | July            |
| Northern hemisphere | November  | August          | February        | May             |
| Southern hemisphere | August    | February        | May             | August          |
| Country   | Population        | Country   | Population   | Country     | Population   | Country   | Population | Country   | Population |
|-----------|-------------------|-----------|--------------|-------------|--------------|-----------|------------|-----------|------------|
| China     | 1476592197        | Austria   | 9015714      | America     | 332716351    | Marshall Islands | 60147     | Morocco   | 37232554  |
| Israel    | 8741690           | Norway    | 5473843      | Honduras    | 9981560      |           |            | Nigeria   | 209422421  |
|           |                   |           |              |             |              |           |            | South Africa | 59622023   |
| Total     | 1485333887        | Total     | 14489557     | Total       | 342697911    | Total     | 60147      | Total     | 306276998  |
Figure 1 (a) Weekly Influenza Morbidity of Eight Countries in Northern Hemisphere during Four Seasons

Figure 1 (b) Weekly Influenza Morbidity of Two Countries in Southern Hemisphere during Four Seasons

Figure 1 Weekly Influenza Morbidity of Ten Countries during Four Seasons
Figure 2 High Incidence Season of Influenza

country 1- China, 2- Israel, 3- Norway, 4- Austria, 5- America, 6- Honduras, 7- Marshall Islands, 8- Morocco, 9- Nigeria, 10- South Africa
Figure 3 (a) Weekly COVID-19 Morbidity of Eight Countries in Northern Hemisphere during Four Seasons
Figure 3 (b) Weekly COVID-19 Morbidity of Two Countries in Southern Hemisphere during Four Seasons

Figure 3 Weekly COVID-19 Morbidity of Ten Countries during Four Seasons
Figure 4 High Incidence Season of COVID-19
Figure 5 High Incidence Region of Influenza
(continent 1- Asia, 2- Europe, 3- Americas, 4- Oceania, 5- Africa)
Figure 6: High Incidence Region of COVID-19
(continent 1- Asia, 2- Europe, 3- Americas, 4- Oceania, 5- Africa)
### Table 3 Results of Variance Analysis for Distribution Features

| Analysis Purpose               | Grade   | Season/Continent   | P of K-S Test | P of Kruskal Wallis |
|-------------------------------|---------|--------------------|---------------|---------------------|
| **High Incidence Season of Influenza** | 3211.77 | season 4 (winter) | <0.001        | <0.001              |
|                               | 2686.42 | season 1 (spring)  |               |                     |
|                               | 2572.04 | season 3 (autumn)  |               |                     |
|                               | 2000.92 | season 2 (summer)  |               |                     |
| **High Incidence Season of COVID-19** | 334.91  | season 3 (autumn)  | <0.001        | <0.001              |
|                               | 285.52  | season 2 (summer)  |               |                     |
|                               | 257.55  | season 1 (spring)  |               |                     |
|                               | 231.65  | season 4 (winter)  |               |                     |
| **High Incidence Region of Influenza** | 4003.91 | continent 4 (Oceania) | <0.001        | <0.001              |
|                               | 3426.81 | continent 3 (Americas) |               |                     |
| **High Incidence Region of COVID-19** | 2512.92 | continent 2 (Europe) | <0.001        | <0.001              |
|                               | 2272.88 | continent 1 (Asia) |               |                     |
|                               | 1925.28 | continent 5 (Africa) |               |                     |
| **High Incidence Region of COVID-19** | 356.23  | continent 3 (Americas) | <0.001        | <0.001              |
|                               | 317.21  | continent 2 (Europe) |               |                     |
|                               | 268.48  | continent 5 (Africa) |               |                     |
|                               | 267.99  | continent 1 (Asia)  |               |                     |
|                               | 66.69   | continent 4 (Oceania) |               |                     |
| Analysis Purpose                  | Country   | P          | Median      | Interquartile Range          |
|----------------------------------|-----------|------------|-------------|-------------------------------|
| Normality Test of Influenza Morbidity per Week | China     | <0.001     | 0.0000194939 | 0.0000471859 |
|                                  | Israel    | <0.001     | 0.0010687180 | 0.0051945008 |
|                                  | Austria   | <0.001     | 0.0001523000 | 0.0042965970 |
|                                  | Norway    | <0.001     | 0.0052002475 | 0.0333135778 |
|                                  | America   | <0.001     | 0.0039992415 | 0.0043208635 |
|                                  | Honduras  | <0.001     | 0.0053472760 | 0.0055175492 |
|                                  | Marshall Islands | <0.001     | 0.0263977610 | 0.0489017460 |
|                                  | Morocco   | <0.001     | 0.0034121485 | 0.0042637195 |
|                                  | Nigeria   | <0.001     | 0.0000070821 | 0.0000189349 |
|                                  | South Africa | <0.001     | 0.0000211969 | 0.00001062515 |
| Normality Test of COVID-19 Morbidity per Week | China     | <0.001     | 0.0000186556 | 0.0000446202 |
|                                  | Israel    | <0.001     | 0.0529703140 | 0.1325014740 |
|                                  | Austria   | <0.001     | 0.0097429050 | 0.1066374900 |
|                                  | Norway    | <0.001     | 0.0070738570 | 0.0291102170 |
|                                  | America   | <0.001     | 0.0833752790 | 0.0949811780 |
|                                  | Honduras  | <0.001     | 0.0254737660 | 0.0444137090 |
|                                  | Marshall Islands | <0.001     | 0.0000000000 | 0.0000000000 |
|                                  | Morocco   | <0.001     | 0.0053008310 | 0.0409076970 |
|                                  | Nigeria   | <0.001     | 0.0005924380 | 0.0015130247 |
|                                  | South Africa | <0.001     | 0.0190632040 | 0.0509404100 |
| Analysis Purpose | Grade     | Country                     | P of Kruskal Wallis |
|------------------|-----------|-----------------------------|----------------------|
| Differences of Influenza Morbidity amid Different Countries | 4003.91   | country 7 (Marshall Islands) | <0.001               |
|                  | 3547.98   | country 5 (America)         |                      |
|                  | 3305.65   | country 6 (Honduras)        |                      |
|                  | 3164.49   | country 8 (Morocco)         |                      |
|                  | 3023.02   | country 4 (Norway)          |                      |
|                  | 2972.34   | country 2 (Israel)          |                      |
|                  | 2002.83   | country 3 (Austria)         |                      |
|                  | 1573.42   | country 1 (China)           |                      |
|                  | 1446.56   | country 10 (South Africa)   |                      |
|                  | 1164.81   | country 9 (Nigeria)         |                      |
| Differences of COVID-19 Morbidity amid Different Countries | 405.85    | country 5 (America)         | <0.001               |
|                  | 376.16    | country 2 (Israel)          |                      |
|                  | 339.85    | country 3 (Austria)         |                      |
|                  | 320.35    | country 10 (South Africa)   |                      |
|                  | 306.60    | country 6 (Honduras)        |                      |
|                  | 294.56    | country 4 (Norway)          |                      |
|                  | 293.65    | country 8 (Morocco)         |                      |
|                  | 191.45    | country 9 (Nigeria)         |                      |
|                  | 159.82    | country 1 (China)           |                      |
|                  | 66.69     | country 7 (Marshall Islands)|                      |
| Cluster  | Number | Cluster Centers | Country |
|----------|--------|-----------------|---------|
|          |        | Cluster Centers |         |
|          |        | Year 2016       |         |
|          |        | Week 27         |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 | China |
|          |        | Morbidity 0.0000420151 |         |
| Cluster 1| 524    | Week 2016       |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Year 2016       |         |
|          |        | Week 27         |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
| Cluster 2| 4716   | Week 2016       |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
| Cluster 1| 495    | Week 2016       |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 |         |
|          |        | Morbidity 0.0000420151 |         |
| Cluster 2| 55     | Week 2016       |         |
|          |        | Country 1       |         |
|          |        | Continent 1     |         |
|          |        | Population 1406170204 | China |
|          |        | Morbidity 0.0000420151 |         |
| Country        | Spearman's Rank Correlation Coefficient $\rho$ | $P$ of Spearman Test | Correlation       |
|----------------|----------------------------------------------|----------------------|-------------------|
| China          | 0.412                                        | 0.002                | positive correlation |
| Israel         | -0.402                                       | 0.002                | negative correlation |
| Austria        | -0.159                                       | 0.245                | uncorrelation      |
| Norway         | -0.057                                       | 0.678                | uncorrelation      |
| America        | -0.227                                       | 0.095                | uncorrelation      |
| Honduras       | 0.527                                        | <0.001               | positive correlation |
| Marshall Islands | 0.092                                      | 0.503                | uncorrelation      |
| Morocco        | -0.639                                       | <0.001               | negative correlation |
| Nigeria        | -0.449                                       | 0.001                | negative correlation |
| South Africa   | -0.238                                       | 0.080                | uncorrelation      |
Figure 7 ARMA Model of Influenza during 2011-2018
Figure 8 Time Series of Influenza during 2019-2021
Figure 9 The Original and The Forecasted Time Series of Influenza in 2019-2021
(blue line- the forecasted time series; orange line- the original time series;
abscissa- week counted from Jan. 1st, 2019; ordinate- morbidity)
| Country         | AR(p) | MR(q) | d  | RMSE |
|-----------------|-------|-------|----|------|
| China           | 2     | 2     | 0  | 0.0000 |
| Israel          | 2     | 2     | 0  | 0.0031 |
| Austria         | 2     | 0     | 0  | 0.0012 |
| Norway          | 3     | 2     | 0  | 0.0135 |
| America         | 2     | 0     | 0  | 0.0007 |
| Honduras        | 1     | 2     | 0  | 0.0017 |
| Marshall Islands| 1     | 4     | 0  | 0.0309 |
| Morocco         | 1     | 0     | 0  | 0.0010 |
| Nigeria         | 0     | 2     | 1  | nah   |
| South Africa    | 3     | 0     | 0  | 0.0001 |

| Country          | AR(p) | MR(q) | d  | RMSE |
|------------------|-------|-------|----|------|
| China            | 1     | 0     | 1  | nan  |
| Israel           | 2     | 0     | 0  | 0.0023 |
| Austria          | 1     | 0     | 1  | nan  |
| Norway           | 0     | 1     | 1  | nan  |
| America          | 1     | 1     | 0  | 0.0015 |
| Honduras         | 0     | 3     | 1  | nan  |
| Marshall Islands | 1     | 0     | 0  | 0.0320 |
| Morocco          | 0     | 1     | 1  | nan  |
| Nigeria          | 2     | 0     | 1  | nan  |
| South Africa     | 1     | 0     | 1  | nan  |
## Table 9 Results of Variance Analysis for Difference between the Original and the Forecasted Time Series of Influenza in 2019-2021

| Country     | Grade | The Forecasted | P of K-S Test | P of Mann-Whitney U |
|-------------|-------|----------------|---------------|---------------------|
| China       | 126.83| The Original   | <0.001        | <0.001              |
|             | 88.17 | The Forecasted | <0.001        |                     |
| Israel      | 138.58| The Original   | <0.001        | <0.001              |
|             | 76.42 | The Forecasted | <0.001        |                     |
| Austria     | 124.91| The Original   | <0.001        | <0.001              |
|             | 90.09 | The Forecasted | <0.001        |                     |
| Norway      | 124.34| The Original   | <0.001        | <0.001              |
|             | 90.66 | The Forecasted | <0.001        |                     |
| America     | 96.82 | The Original   | <0.001        | 0.012               |
|             | 118.18| The Forecasted | <0.001        |                     |
| Honduras    | 151.43| The Original   | <0.001        | <0.001              |
|             | 63.57 | The Forecasted | <0.001        |                     |
| Marshall Islands | 146.12| The Original   | <0.001        | <0.001              |
|             | 68.88 | The Forecasted | <0.001        |                     |
| Morocco     | 136.62| The Original   | <0.001        | <0.001              |
|             | 78.38 | The Forecasted | <0.001        |                     |
| Nigeria     | 83.73 | The Original   | 0.2000        | <0.001              |
|             | 131.27| The Forecasted | <0.001        |                     |
| South Africa | 151.83| The Original   | <0.001        | <0.001              |
|             | 63.17 | The Forecasted | <0.001        |                     |
| Countries       | When the COVID-19 firstly reported* | When the first abnormal peak started on the original time series** |
|-----------------|-------------------------------------|---------------------------------------------------------------|
| China           | 2019-12-31<sup>a</sup>             | 2019-09-30 (40th week)                                        |
| Israel          | 2020-02-20<sup>b</sup>             | 2019-09-30 (40th week)                                        |
| Austria         | 2020-02-25<sup>c</sup>             | 2018-12-31 (1st week)                                         |
| Norway          | 2020-02-26<sup>d</sup>             | 2018-12-31 (1st week)                                         |
| America         | 2020-01-20<sup>e</sup>             | 2019-07-22 (30th week)                                        |
| Honduras        | 2020-03-11<sup>f</sup>             | 2020-03-11 (63rd week)                                        |
| Marshall Islands| 2020-10-27<sup>g</sup>             | 2019-04-08 (15th week)                                        |
| Morocco         | 2020-03-02<sup>h</sup>             | 2018-12-31 (1st week)                                         |
| Nigeria         | 2020-02-27<sup>i</sup>             | 2018-12-31 (1st week)                                         |
| South Africa    | 2020-03-05<sup>j</sup>             | 2019-01-28 (5th week)                                         |

*These datas came from:

  a. https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019
  b. https://www.sohu.com/a/374822696_162522
  c. https://baijiahao.baidu.com/s?id=1659569615064840180&wfr=spider&for=pc
  d. https://baijiahao.baidu.com/s?id=1659648502481738968&wfr=spider&for=pc
  e. https://www.paho.org/en/covid-19-situation-reports?topic=All&d%5Bmin%5D=&d%5Bmax%5D=&
  f. https://www.paho.org/en/covid-19-global-and-regional-daily-update?topic=All&d%5Bmin%5D=&d%5Bmax%5D=&
  g. https://baijiahao.baidu.com/s?id=1681869314040782482&wfr=spider&for=pc
  h. https://baijiahao.baidu.com/s?id=1660105273178454266&wfr=spider&for=pc
  i. https://www.afro.who.int/countries/979/news
  j. https://covid19.who.int/region/afro/country/za

**The numbers of weeks in brackets in this column represented the numbers of weeks counted from December 31, 2018.